Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E 2 synthesis

Journal of Infectious Diseases

Volumn 194, Issue 6, 2006, Pages 846-854

  Barreto De Souza, Victor ^a   Pacheco, Graziela J ^a   Silva, Adrians R ^a   Castro Faria Neto, Hugo C ^a   Bozza, Patrícia T ^a   Saraiva, Elvira M ^a   Bou Habib, Dumith Chequer ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROSTAGLANDIN E2; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE INDUCTION; GENUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEISHMANIA; MACROPHAGE; NONHUMAN; NORMAL HUMAN; OPPORTUNISTIC INFECTION; PARASITE DEVELOPMENT; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; LEISHMANIA; LEISHMANIASIS; MACROPHAGES; PYRAZOLES; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748431196     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506618     Document Type: Article

References (43)

1. Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous liaisons. Mol Immunol 2005; 42:195-212.
2. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55:209-25.
3. Igarashi T, Brown CR, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001; 98:658-63.
4. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276:1857-61.
5. Wahl SM, Greenwell-Wild T, Peng G, et al. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci USA 1998; 95:12574-9.
6. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766-70.
7. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
8. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol 2004; 113:81-8.
9. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97:3-15.
10. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol 2003; 97:29-45.
11. Preiser W, Cacopardo B, Nigro L, et al. Immunological findings in HIV-Leishmania coinfection. Intervirology 1996; 39:285-8.
12. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998; 56:1009-18.
13. Karp CL, Neva FA. Tropical infectious diseases in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 28:947-63.
14. Gillis D, Klaus S, Schnur LF, et al. Diffusely disseminated cutaneous Leishmania major infection in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1995; 14:247-9.
15. Da-Cruz AM, Filgueiras DV, Coutinho Z, et al. Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. Mem Inst Oswaldo Cruz 1999; 94:537-42.
16. Wolday D, Akuffo H, Fessahaye G, Valantine A, Britton S. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis 1998; 30:29-34.
17. Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol 2003; 3:97-107.
18. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type I Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-87.
19. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-31.
20. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500.
21. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2:960-4.
22. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999; 96:8324-6.
23. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV-1 Tat: a polypeptide for all seasons. Immunol Today 1998; 19:543-5.
24. Zauli G, Davis BR, Re MC, Visani G, Furlini G, La Placa M. tat protein stimulates production of transforming growth factor-beta 1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood 1992; 80:3036-43.
25. Barton CH, Biggs TE, Mee TR, Mann DA. The human immunodeficiency virus type 1 regulatory protein Tat inhibits interferon-induced iNos activity in a murine macrophage cell line. J Gen Virol 1996; 77:1643-7.
26. Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257:545-8.
27. Reed SG. TGF-beta in infections and infectious diseases. Microbes Infect 1999; 1:1313-25.
28. Lima RG, Van Weyenbergh J, Saraiva EM, Barral-Netto M, Galvão-Castro B, Bou-Habib DC. The replication of human immunodeficiency virus type 1 in macrophages is enhanced after phagocytosis of apoptotic cells. J Infect Dis 2002; 185:1561-6.
29. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999; 339:607-14.
30. Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 2000; 74:10551-62.
31. Vanloubbeeck Y, Jones DE. The immunology of Leishmania infection and the implications for vaccine development. Ann NY Acad Sci 2004; 1026:267-72.
32. Gibellini D, Zauli G, Re MC, et al. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994; 88:261-7.
33. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101:890-8.
34. Freire-de-Lima CG, Nascimento DO, Soares MB, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 2000; 403:199-203.
35. Ribeiro-Gomes FL, Otero AC, Gomes NA, et al. Macrophage interactions with neutrophils regulate Leishmania major infection. J Immunol 2004; 172:4454-62.
36. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-82.
37. Picker LJ, Watkins DI. HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005; 6:430-2.
38. Couppie P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165-71.
39. Wahl SM, Greenwell-Wild T, Peng G, Ma G, Orenstein JM, Vazquez N. Viral and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc Biol 2003; 74:726-35.
40. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum promotes replication of HIV type 1 in human lymphoid tissue cultured ex vivo by inducing secretion of the proinflammatory cytokines TNF-alpha and IL-1 alpha. J Immunol 2004; 172:3086-93.
41. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-8.
42. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16.
43. Vodovotz Y. Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1997; 1:3-17.